Wave Life Sciences Ltd. (WVE) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

11/25

Growth 2 Margin 2 Expansion 3 Platform 2 Financial 2

latest quarter score

Earnings Reports

11
Wave Life Sciences (WVE) Q2 2026: R&D Spend Climbs 18% as Obesity and RNA Editing Pipeline Expands
July 30, 2026
11
Wave Life Sciences (WVE) Q1 2026: Cash Position Extends Runway Into 2028 as RNA Platform Advances
April 28, 2026
8
Wave Life Sciences (WVE) Q4 2025: R&D Spend Rises 15% as Obesity and RNA Editing Pipeline Accelerates
February 26, 2026
12
Wave Life Sciences (WVE) Q3 2025: Inhibin E Knockdown Reaches 85%, Unlocking Durable Obesity Data Path
November 10, 2025
8
Wavelife Sciences (WVE) Q2 2025: Obesity Cohort Expansion to 32 Signals Accelerated Pipeline Ambition
July 30, 2025
9
Wave Life Sciences (WVE) Q1 2025: R&D Spend Climbs 22% as Obesity and AATD Programs Near Data Inflection
July 07, 2025
Wave Life Sciences (WVE) Q4 2024: RNA Editing Advances Drive Pipeline Expansion with $302M Cash Runway Into 2027
March 04, 2025

Browse all companies